Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced the company plans to participate in the upcoming Credit Suisse virtual Healthcare Conference.
GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the company plans to participate in the upcoming Credit Suisse virtual Healthcare Conference.
Management is scheduled to present Wednesday, November 11, 2020 at 10:15 am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ CGM Systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105006060/en/
Senseonics Investor Relations Contact:
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com
Source: Senseonics Holdings, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20201105006060/en
